Evolus, Inc..
EOLS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Evolus, Inc. is a performance beauty company with a focus on providing physicians and their patients with innovative aesthetic products. The company's flagship product is Jeuveau (prabotulinumtoxinA-xvfs), a botulinum toxin type A indicated for the temporary improvement in the appearance of moderate...Show More
Better Health for All
-80
Evolus' core products, Jeuveau and Evolysse, are aesthetic treatments for wrinkles and frown lines.
1
While they aim to improve appearance and satisfaction, they carry significant, life-threatening health risks, including problems swallowing, speaking, breathing, vision abnormalities, blindness, stroke, heart attack, and death.
2
These products offer no direct health benefits in the context of medical treatment or wellness, and all revenue is derived from these cosmetic procedures with severe potential harms. Clinical trials for Jeuveau reported adverse event rates up to 42.0%, with some serious adverse events and one death, though not assessed as study drug related.
3
The combined eyelid ptosis rate for two studies was 0.9%.
4
The products are not for use in children, and safety has not been studied during pregnancy or breastfeeding.
5
Pricing for Jeuveau ranges from $379 to $549 per vial, and Evolysse from $169 to $299 per syringe, with a $100 cancellation fee for Club Evolus if cancelled within three months.
6
The company provides important safety information, including a boxed warning for Jeuveau, and offers a privacy policy with a "Do Not Sell My Personal Information" option.
7
Evolus offers an Employee Assistance Program and personalized coaching for mental well-being, and competitive medical, dental, and vision benefits for employees.
8
The company also provides some digital education for healthcare professionals.
9
Fair Money & Economic Opportunity
0
Evolus, Inc. is a performance beauty company focused on aesthetic products.
1
The provided articles contain no evidence that the company engages in activities related to lending, insuring, moving, or storing money for consumers, which is the core focus of the 'Fair Money & Economic Opportunity' value. Therefore, all KPIs are scored as 0, indicating that they are not applicable as the company's core business lies outside financial services and it does not offer consumer credit products or manage customer finance data.
Fair Pay & Worker Respect
20
The company has an overall employee rating of 4.1 out of 5 stars, based on 48 reviews, which translates to an engagement score of 82%.
Additionally, 80% of employees would recommend working at the company, and 83% approve of the CEO.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess Evolus, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Evolus, Inc. on Honest & Fair Business.
Kind to Animals
-70
Evolus, Inc. states that its biological product development involves preclinical laboratory and animal tests.
1
The company's primary release procedure for Jeuveau uses an animal-based potency assay, specifically the median intraperitoneal lethal dose (LD50) in mice, to determine potency.
2
This LD50 test is demanded by the European Pharmacopoeia for each batch of botulinum toxin.
3
While a post-marketing commitment was issued to develop a non-animal-based potency assay by January 2021, this is a commitment to develop, not evidence of current alternative testing usage.
4
Evolus, Inc. is listed among companies that engage in animal testing.
5
The company does not provide evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing and sourcing standards.
6
No War, No Weapons
0
No specific, quantitative evidence was found in the provided articles to assess Evolus, Inc. against any of the KPIs for the 'No War, No Weapons' ethical value. While the company states it actively participates in the movement to ban conflict minerals and audits suppliers regularly for slave labor, no specific percentages of conflict-free supply chain or defined frequencies of human rights due diligence were provided to match the rubric's quantitative thresholds.
1
Additionally, no information was available regarding lobbying activities related to arms control or any other relevant KPIs.
2
Planet-Friendly Business
0
No specific, quantitative data points relevant to the Planet-Friendly Business KPIs were found for Evolus, Inc. (EOLS.US) in the provided articles. The available information consists of aggregated ESG scores and rankings, or qualitative descriptions, which do not meet the rubric's requirement for concrete, measurable evidence.
1
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess Evolus, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles primarily focus on financial performance, general company culture, employee benefits, and product marketing. While some articles mention general community support or inclusivity, they lack the quantitative metrics, specific protocols, or incident reporting required by the rubric to score any KPI.
Safe & Smart Tech
0
No evidence available to assess Evolus, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding Evolus, Inc.'s performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
, which contained some sustainability information, was determined to be about a different company (Eolus, a renewable energy company) and not Evolus, Inc. (EOLS.US).
2